These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 22244830

  • 1. Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo.
    Arai R, Tsuda M, Watanabe T, Ose T, Obuse C, Maenaka K, Minami A, Ohba Y.
    Eur J Cancer; 2012 Oct; 48(15):2417-30. PubMed ID: 22244830
    [Abstract] [Full Text] [Related]

  • 2. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
    Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.
    J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
    [Abstract] [Full Text] [Related]

  • 3. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
    Sánchez-Bailón MP, Calcabrini A, Gómez-Domínguez D, Morte B, Martín-Forero E, Gómez-López G, Molinari A, Wagner KU, Martín-Pérez J.
    Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
    [Abstract] [Full Text] [Related]

  • 4. SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation.
    Cuneo KC, Geng L, Tan J, Brousal J, Shinohara ET, Osusky K, Fu A, Shyr Y, Wu H, Hallahan DE.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1197-203. PubMed ID: 16504759
    [Abstract] [Full Text] [Related]

  • 5. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, Friedrichs N, Kirfel J, Steiner S, Endl E, Wurst P, Heukamp L, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.
    Cancer Res; 2013 Apr 15; 73(8):2518-28. PubMed ID: 23580575
    [Abstract] [Full Text] [Related]

  • 6. Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner.
    Cicha I, Zitzmann R, Goppelt-Struebe M.
    Int J Biochem Cell Biol; 2014 Jan 15; 46():39-48. PubMed ID: 24275091
    [Abstract] [Full Text] [Related]

  • 7. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
    Ischenko I, Guba M, Yezhelyev M, Papyan A, Schmid G, Green T, Fennell M, Jauch KW, Bruns CJ.
    Angiogenesis; 2007 Jan 15; 10(3):167-82. PubMed ID: 17486419
    [Abstract] [Full Text] [Related]

  • 8. Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation.
    Watanabe T, Tsuda M, Tanaka S, Ohba Y, Kawaguchi H, Majima T, Sawa H, Minami A.
    Mol Cancer Res; 2009 Sep 15; 7(9):1582-92. PubMed ID: 19737974
    [Abstract] [Full Text] [Related]

  • 9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 15; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 10. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
    Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE.
    Cancer Res; 2000 Jul 01; 60(13):3655-61. PubMed ID: 10910082
    [Abstract] [Full Text] [Related]

  • 11. A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.
    Hosaka S, Horiuchi K, Yoda M, Nakayama R, Tohmonda T, Susa M, Nakamura M, Chiba K, Toyama Y, Morioka H.
    J Orthop Res; 2012 Sep 01; 30(9):1493-8. PubMed ID: 22359392
    [Abstract] [Full Text] [Related]

  • 12. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
    Ungefroren H, Sebens S, Groth S, Gieseler F, Fändrich F.
    Curr Cancer Drug Targets; 2011 May 01; 11(4):524-35. PubMed ID: 21395548
    [Abstract] [Full Text] [Related]

  • 13. Differential effects on cell motility, embryonic stem cell self-renewal and senescence by diverse Src kinase family inhibitors.
    Tamm C, Galitó SP, Annerén C.
    Exp Cell Res; 2012 Feb 15; 318(4):336-49. PubMed ID: 22197704
    [Abstract] [Full Text] [Related]

  • 14. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.
    Breast Cancer Res Treat; 2011 Nov 15; 130(1):85-96. PubMed ID: 21181437
    [Abstract] [Full Text] [Related]

  • 15. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
    Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA.
    Cancer Res; 2005 Oct 01; 65(19):9038-46. PubMed ID: 16204078
    [Abstract] [Full Text] [Related]

  • 16. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, Shima Y, Nagayama S, Katagiri T, Nakamura Y, Nakamura T, Toguchida J.
    Clin Cancer Res; 2005 Apr 01; 11(7):2702-12. PubMed ID: 15814652
    [Abstract] [Full Text] [Related]

  • 17. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
    Bartscht T, Lehnert H, Gieseler F, Ungefroren H.
    Cancer Chemother Pharmacol; 2012 Aug 01; 70(2):221-30. PubMed ID: 22699812
    [Abstract] [Full Text] [Related]

  • 18. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
    Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S.
    J Hepatol; 2010 Jan 01; 52(1):63-71. PubMed ID: 19913935
    [Abstract] [Full Text] [Related]

  • 19. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y, He L, Zhang L, Chen J, Yi Z, Zhang J, Liu M, Pang X.
    J Pharmacol Exp Ther; 2011 Nov 01; 339(2):403-11. PubMed ID: 21828260
    [Abstract] [Full Text] [Related]

  • 20. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase.
    Sun ZJ, Chen G, Zhang W, Hu X, Huang CF, Wang YF, Jia J, Zhao YF.
    J Pharmacol Exp Ther; 2010 Aug 01; 334(2):500-12. PubMed ID: 20484154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.